Related Experiment Video

Updated: May 4, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K

Protein kinase inhibitors in renal cell carcinoma

Amaury Daste1, Thomas Grellety, Marine Gross-Goupil

  • 1Hôpital Saint-André, Bordeaux University Hospital-CHU Bordeaux, Department of Medical Oncology , 1 Rue Jean Burguet, 33075 Bordeaux , France +33 5 56 79 58 96 ; alain.ravaud@chu-bordeaux.fr.

Expert Opinion on Pharmacotherapy
|December 17, 2013
PubMed
Abstract

Insights

New targeted therapies, including vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (m-TOR) inhibitors, have significantly improved outcomes for metastatic renal cell carcinoma (mRCC). Careful management of these treatments is crucial for patient quality of life.

Area of Science:

  • Oncology
  • Medical Oncology
  • Translational Research

Background:

  • Metastatic renal cell carcinoma (mRCC) historically had poor outcomes with cytokine therapy.
  • Recent advancements include targeted therapies focusing on vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (m-TOR) pathways.
  • Protein kinase inhibitors and monoclonal antibodies targeting these pathways are now standard treatments for renal cell carcinoma (RCC).

Purpose of the Study:

  • To review Phase III clinical trials of targeted therapies for mRCC.
  • To focus on the efficacy, safety, and management of these treatments.
  • To provide an expert opinion on current and future treatment strategies.

Main Methods:

  • Review of Phase III clinical trials.
  • Analysis of protein kinase inhibitors, including anti-angiogenic tyrosine kinase inhibitors (TKIs).
  • Evaluation of m-TOR serine/threonine kinase inhibitors.

Main Results:

  • VEGF TKIs and m-TOR inhibitors have substantially improved mRCC outcomes and survival.
  • Sequential treatments offer survival gains for most patients.
  • These therapies present unique toxicity profiles requiring specific management.

Conclusions:

  • Targeted therapies have revolutionized mRCC treatment, improving survival and quality of life.
  • Effective drug and sequence management is essential for optimizing patient outcomes.
  • Future research will explore VEGF TKIs in adjuvant settings and novel agents challenging current standards.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689